Serum Fibroblast Growth Factor 23 Levels are Associated with Vascular Smooth Muscle Dysfunction in Type 2 Diabetes-Reference-Cited by-同舟云学术

Serum Fibroblast Growth Factor 23 Levels are Associated with Vascular Smooth Muscle Dysfunction in Type 2 Diabetes

Published:2023-12-01 Issue:12 Volume:30 Page:1838-1848
ISSN:1340-3478
Container-title:Journal of Atherosclerosis and Thrombosis
language:en
Short-container-title:JAT

Author:

Natsuki Yuka¹,Morioka Tomoaki¹,Kakutani Yoshinori¹,Yamazaki Yuko¹,Ochi Akinobu¹,Kurajoh Masafumi¹,Mori Katsuhito²,Imanishi Yasuo¹,Shoji Tetsuo³,Inaba Masaaki¹,Emoto Masanori⁴

Affiliation:

1. Department of Metabolism, Endocrinology and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine

2. Department of Nephrology, Osaka Metropolitan University Graduate School of Medicine

3. Department of Vascular Medicine, Osaka Metropolitan University Graduate School of Medicine

4. Vascular Science Center for Translational Research, Osaka Metropolitan University Graduate School of Medicine

Publisher

Japan Atherosclerosis Society

Subject

Biochemistry (medical),Cardiology and Cardiovascular Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/jat/30/12/30_64000/_pdf

Reference51 articles.

1. 1) Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S and Yamashita T: Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A, 2001; 98: 6500-6505

2. 2) Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E and Nishizawa Y: FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int, 2004; 65: 1943-1946

3. 3) Isakova T, Wahl P, Vargas GS, Gutiérrez OM, Scialla J, Xie H, Appleby D, Nessel L, Bellovich K, Chen J, Hamm L, Gadegbeku C, Horwitz E, Townsend RR, Anderson CA, Lash JP, Hsu CY, Leonard MB and Wolf M: Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int, 2011; 79: 1370-1378

4. 4) Gao S, Xu J, Zhang S and Jin J: Meta-Analysis of the Association between Fibroblast Growth Factor 23 and Mortality and Cardiovascular Events in Hemodialysis Patients. Blood Purif, 2019; 47 Suppl 1: 24-30

5. 5) Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, Chonchol M and Investigators H: FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol, 2011; 22: 1913-1922

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of xanthine oxidoreductase inhibitor use with insulin secretory capacity in patients with type 2 diabetes;Journal of Diabetes Investigation;2024-07-30

2. Fibroblast Growth Factors in Cardiovascular Disease;Journal of Atherosclerosis and Thrombosis;2024